Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting

Objectives: There are scarce data on the combination of dolutegravir (DTG) plus rilpivirine (RPV) in the real world, including patients with hepatitis C virus (HCV) coinfection, toxicity or previous failure, or at risk for severe drug–drug interactions (DDIs). Methods: Prospective cohort study of vi...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Jose L. Casado, Marta Monsalvo, María Fontecha, Pilar Vizcarra, Miguel A Rodriguez, María Jesús Vivancos, Santiago Moreno
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Taylor & Francis Group 2019-04-01
Saila:	HIV Research & Clinical Practice
Gaiak:	dual therapy dolutegravir rilpivirine switching simplification
Sarrera elektronikoa:	http://dx.doi.org/10.1080/15284336.2019.1628460
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!